Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 2/20 | 0.39 |
| ▸ | MAP3K12 | Q12852 | 3/20 | 0.38 |
| ▸ | KHK | P50053 | 4/20 | 0.37 |
| ▸ | PTPN11 | Q06124 | 2/20 | 0.36 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.35 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.35 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.35 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.35 |
| ▸ | CHRNB3 | Q05901 | 1/20 | 0.35 |
| ▸ | CHRM4 | P08173 | 3/20 | 0.35 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.35 |
| ▸ | ME2 | P23368 | 1/20 | 0.35 |
| ▸ | ME1 | P48163 | 1/20 | 0.35 |
| ▸ | ME3 | Q16798 | 1/20 | 0.35 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.34 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.34 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL907705 | 0.88 | SLC9A1 (0.36) | MAP3K12KHKPTPN11 | |
| SCHEMBL3877824 | 0.85 | MALT1 (0.41) | MAP3K12KHKPTPN11CHRM4 | |
| SCHEMBL908009 | 0.85 | MAP3K12 (0.38) | MAP3K12KHKPTPN11CHRNB1CHRNB2 | |
| SCHEMBL3880083 | 0.83 | SLC9A1 (0.45) | MAP3K12PTPN11CHRNB1CHRNB2CHRNB4 | |
| SCHEMBL908061 | 0.83 | CASP1 (0.39) | MAP3K12KHKPTPN11 | |
| SCHEMBL907961 | 0.83 | KHK (0.39) | MGLLMAP3K12KHK | |
| SCHEMBL908003 | 0.82 | EGLN2 (0.43) | MAP3K12KHKPTPN11CHRNB1CHRNB2 | |
| SCHEMBL3878956 | 0.82 | MALT1 (0.38) | MAP3K12KHKCHRM4 | |
| SCHEMBL3878041 | 0.82 | MALT1 (0.44) | MAP3K12CHRM4 | |
| SCHEMBL908517 | 0.82 | MAP3K12 (0.37) | MAP3K12KHK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7662830-B2 | Substituted biaryl piperazinyl-pyridine analogues | NEUROGEN CORPORATION (US) | 2010-02-16 | — | — | US | disclosed |
| US-20060122394-A1 | Substituted biaryl piperazinyl-pyridine analogues | NEUROGEN CORPORATION | 2006-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060122394-A1 | Substituted biaryl piperazinyl-pyridine analogues | GPR88, PRLHR, GPR68 | MGLL 2552/4885MAP3K12 2343/4885KHK 2971/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.